A multiple sclerosis treatment fueled TG Therapeutics’ growth as it made Deloitte’s list for a third straight year.
TG Therapeutics (NASDAQ: TGTX) has been recognized for the third consecutive year as one of North America's fastest-growing companies, ranking number 5 on the 2026 Deloitte Technology Fast 500. This growth, measured from fiscal years 2022 to 2025, was primarily driven by the success of BRIUMVI®, its treatment for relapsing forms of multiple sclerosis, which received FDA approval in December 2022. The company's CEO, Michael S. Weiss, attributed this achievement to the team's commitment and BRIUMVI's strong market acceptance within the multiple sclerosis community.
TG Therapeutics: 3 Key Takeaways for Long-Term Investors
TG Therapeutics (NASDAQ:TGTX) has raised its full-year 2026 global revenue guidance to $1 billion due to strong commercial momentum for BRIUMVI, its multiple sclerosis therapy. The company's expanding prescriber adoption drove U.S. BRIUMVI revenue up 52% year over year, generating operating cash flow to fund pipeline expansion. Management is now focusing on leveraging this commercial success into new formulations and indications, including a subcutaneous option for patients who prefer home administration.
TG Therapeutics, Inc. (TGTX) latest stock news and headlines
This article provides a compilation of recent news and headlines concerning TG Therapeutics, Inc. (TGTX). Key updates include the company lifting its revenue guidance, beating Q3 earnings and revenue estimates for 2026, and a 61% jump in revenue as per their Q3 2026 earnings call highlights. The stock's performance overview shows significant trailing total returns year-to-date, one-year, and three-year periods, outperforming the S&P 500.
TG Therapeutics (TGTX) Lifts Revenue Guidance As Investors Ask If The Stock Is Pricey
TG Therapeutics (TGTX) reported strong third-quarter 2026 results with robust revenue and slimmer profits, leading to a raised full-year revenue guidance of approximately US$1 billion. The stock has seen significant gains, with a 30-day return of 16.06% and a year-to-date gain of 119.47%, prompting investors to question its valuation. While a bearish narrative suggests the stock is overvalued at $64.26 compared to a fair value of $28.81 due to rising costs and pipeline spending, a discounted cash flow (DCF) model indicates it might be undervalued, trading 63% below an estimated future cash flow value of $172.03.
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up
TG Therapeutics (TGTX) reported strong third-quarter 2026 earnings and revenues, surpassing Zacks Consensus Estimates, primarily driven by the robust performance of its drug Briumvi. Following these positive results and an increased full-year 2026 global revenue guidance to approximately $1 billion, the company's stock rose significantly. The company also provided updates on its pipeline, including new formulations and expanded indications for Briumvi.
TG Therapeutics stock hits 52-week high at 63.68 USD
TG Therapeutics (TGTX) stock reached a new 52-week high of $63.68, currently trading at $64.09 with an impressive 113% year-to-date return. This growth is supported by strong fundamentals including a 76% revenue surge and 82% gross profit margins, with InvestingPro indicating the stock is still undervalued. The company also reported strong Q3 2026 revenue driven by BRIUMVI sales, exceeding expectations despite a slight earnings per share miss.
TG Therapeutics (TGTX) Q3 2026 Earnings Call Transcript
TG Therapeutics (TGTX) reported strong Q3 2026 results, with global revenue reaching $259.9 million, driven by robust U.S. BRIUMVI sales. The company raised its full-year global revenue guidance to $1 billion and discussed significant progress in its clinical development programs, including long-term efficacy data for BRIUMVI and early positive results for its CAR T cell therapy, azer-cel, in progressive MS. Management highlighted plans for a simplified IV initiation dose and a subcutaneous formulation of BRIUMVI as key growth drivers.
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics reported strong third-quarter 2026 financial results, achieving approximately $260 million in global revenue, including $233 million from BRIUMVI U.S. net product sales. The company raised its full-year 2026 total global revenue guidance to approximately $1 billion, up from $950 million, and also increased BRIUMVI U.S. net product revenue guidance. Key clinical data presentations at MSToronto2026 highlighted sustained BRIUMVI efficacy and safety, progress toward a quarterly subcutaneous treatment, and initial positive data for Azer-cel in Progressive MS and BRIUMVI in Myasthenia Gravis and Schizophrenia.
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call
TG Therapeutics (TGTX) raised its 2026 revenue outlook after strong third-quarter sales of its multiple sclerosis treatment, BRIUMVI, which climbed 52% in the U.S. The company now projects approximately $1 billion in total global revenue for the year and expects a stronger fourth quarter. Additionally, TG Therapeutics is developing new dosing options for BRIUMVI, including a simplified intravenous regimen and a self-administered subcutaneous version, and presented positive long-term and early-stage data for its therapies.
TG Therapeutics Releases Q3 2026 Financial Results
TG Therapeutics (TGTX) reported strong financial results for Q3 2026, exceeding analyst expectations with diluted earnings per share of $0.35 against an estimated $0.26, and revenue of $259.9M, surpassing the $245.4M consensus. The company's U.S. net product revenue from BRIUMVI reached $232.6M, driving significant growth. TG Therapeutics also provided a full-year revenue guidance of $1.00B, reflecting confidence in its commercial strategy.
TG Therapeutics Q3 2026 Earnings Call Transcript
TG Therapeutics reported strong Q3 2026 financial results with global revenue of $260 million, driven by $233 million in U.S. Briumvi net revenue, leading the company to raise its full-year global revenue guidance to $1 billion. Strategic initiatives include potential approval for a consolidated IV initiation dose by mid-2027 and the launch of subcutaneous Briumvi in 2028, aiming to expand market share in multiple sclerosis and new indications like myasthenia gravis and treatment-resistant schizophrenia. The company emphasized its commitment to scientific innovation and disciplined capital allocation to drive long-term value creation.
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say
TG Therapeutics (TGTX) reported its Q3 2026 earnings, with revenues of $259.94 million, an increase of 60.7% year-over-year, surpassing the Zacks Consensus Estimate. The company also delivered an EPS of $0.35, beating the consensus estimate by 25%. Key metrics like product revenue and U.S. BRIUMVI revenue were closely watched, and the stock currently holds a Zacks Rank #1 (Strong Buy).
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics (TGTX) reported strong third-quarter 2026 financial results, with total global revenue reaching $259.9 million, driven by $232.6 million in BRIUMVI U.S. net product revenue. The company raised its full-year 2026 total global revenue guidance to approximately $1 billion from $950 million. Despite a sharp decline in net income due to a one-time tax benefit in the prior year, TG Therapeutics repurchased about $100 million of its stock and reported a healthy cash position of $556.7 million.
TG Therapeutics: Q3 Earnings Snapshot
TG Therapeutics Inc. (TGTX) reported strong third-quarter earnings, with net income of $55.5 million and 35 cents per share, surpassing analyst expectations of 28 cents per share. The biopharmaceutical company also exceeded revenue forecasts, posting $259.9 million against an anticipated $247.2 million.
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
TG Therapeutics announced strong financial results for the third quarter of 2026, exceeding expectations and leading the company to raise its full-year global revenue guidance to approximately $1 billion, primarily driven by BRIUMVI sales. The company also highlighted positive clinical data for BRIUMVI across multiple sclerosis and other indications, as well as a significant share repurchase. Looking ahead, TG Therapeutics anticipates several important catalysts over the next 18-24 months, including pivotal Phase 3 subcutaneous BRIUMVI results and potential new launches.
TG Therapeutics Inc (NKB2.SG) stock price, news, quote and history
This article provides detailed financial information for TG Therapeutics Inc (NKB2.SG), including its current stock price, historical performance data, and key financial statistics. It highlights the stock's significant returns over various periods, outperforming the S&P 500. The page also offers valuation measures, profitability metrics, and balance sheet figures for the company.
TG Therapeutics, Inc. (TGTX) Seasonal returns chart
The article displays a seasonal returns chart for TG Therapeutics, Inc. (TGTX), showing the average monthly price return from 2016 to 2026. It provides current stock information including its real-time Nasdaq price, daily change, and after-hours trading activity. The page also features links to various financial data sections for TGTX.
TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
TG Therapeutics, Inc. (NASDAQ: TGTX) announced it will host a conference call on Monday, November 9, 2026, at 8:30 AM ET to discuss its third-quarter 2026 financial results and provide a business outlook. Michael S. Weiss, Chairman and CEO, will lead the call, which will also be accessible via webcast on the company's website. The company will issue a press release with its financial results prior to the call.
TG Therapeutics stock hits 52-week high at 59.39 USD
TG Therapeutics (TGTX) stock reached a new 52-week high of $59.39, reflecting a 70.76% increase over the past year and a nearly 95% year-to-date return. Despite a market capitalization of $8.3 billion and a P/E ratio of 20.85, InvestingPro analysis indicates the stock remains undervalued relative to its Fair Value. The company recently reported strong Q2 2026 revenues of $240.5 million, largely driven by Briumvi sales, prompting H.C. Wainwright to raise its price target to $78 with a "Buy" rating.
TG Therapeutics Stock Climbs 15% On A 6-Day Winning Streak
Shares of TG Therapeutics (TGTX) have risen 15.1% over the last six trading sessions, adding $1.1 billion to its market value to reach $8.7 billion. This performance significantly outpaced the S&P 500, which lost 1.1% during the same period. The company's strong fundamentals, including 76.1% revenue growth and an operating margin of 17.1%, support the stock's recent surge.
TG Therapeutics, Inc. (TGTX) Stock forecasts
Argus has raised its target price for TG Therapeutics Inc (TGTX) to $62.00. The company is a commercial-stage biopharmaceutical firm specializing in treatments for B-cell diseases. This report suggests a positive outlook for TGTX.
Weekly Recap: TG Therapeutics (TGTX) cash $612.3M and 89% EDSS stability
TG Therapeutics (TGTX) reported a significant increase in cash and investments, reaching $612.3 million by June 30, 2026. The company also released ENABLE real-world BRIUMVI data showing robust B-cell depletion, no new MRI lesions, and 89% of patients achieving stable or improved EDSS at Day 90, highlighting strong liquidity and positive clinical outcomes.
Funds from operations of TG Therapeutics, Inc. – FWB:NKB2
This article displays the "Funds from operations" for TG Therapeutics, Inc. (FWB:NKB2) on the Frankfurt Stock Exchange via TradingView. The content shows a financial data point with no trades recorded and minimal other information, primarily focusing on the company's financial overview.
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics has announced its schedule for data presentations at MSToronto2026, a key event for the company to share its latest research and clinical trial results. This announcement highlights the company's commitment to advancing treatments and informing the medical community about its progress in the field.
TGTX Stock Bucks Broader Biotech Selloff As Multiple Sclerosis Therapy Shows Promising Early Results — Here’s What Investors Need To Know
TG Therapeutics (TGTX) saw its stock rise after reporting positive early results from a Phase 1 trial for Azer-cel, an experimental cell therapy for progressive multiple sclerosis. The therapy showed that 89% of evaluable patients had stable or improved disability scores after 90 days, with no severe CAR-T-related toxicities. Retail sentiment was bullish, with the stock surging nearly 90% in 2026.
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TG Therapeutics announced initial Phase 1 study results for azercabtagene zapreleucel (azer-cel), an allogeneic CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis. The data, presented at MSToronto2026, showed an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities and stable or improved disability scores in 89% of evaluable participants despite prior progression on high-efficacy therapies. The company plans to continue dose escalation and evaluate longer-term outcomes.
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
TG Therapeutics announced initial Phase 1 study results for azercabtagene zapreleucel (azer-cel), an allogeneic CD19-directed CAR T-cell therapy, in patients with progressive multiple sclerosis. The study showed an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities, and 89% of evaluable participants had stable or improved disability scores at Day 90, despite prior progression. These findings suggest potential clinical activity and therapeutic advance for progressive MS.
TG Therapeutics, Inc. Estimates – NASDAQ:TGTX
This article provides an overview of TG Therapeutics, Inc. (NASDAQ: TGTX) financials and estimates available on TradingView. It highlights features like reported financial data, analyst estimates across various statements, and tools to compare actual results with average, high, and low estimates, along with visualizing trends. The content is presented as a financial data resource and not as investment advice.
TG Therapeutics (TGTX) Back In Focus As BRIUMVI Data Strengthens The Bull Case
TG Therapeutics (TGTX) is gaining renewed investor attention following new BRIUMVI data presented at MSToronto2026 and a five-year comparison study, highlighting long-term multiple sclerosis outcomes and dosing convenience. These disclosures, including seven-year follow-up from trials and real-world results, reinforce the bullish case for the US$7.5 billion biotech, which has seen its share price rise 81.56% year to date. Analysts currently consider TGTX undervalued by 24% against a fair value of $69.71, with the upcoming launch of subcutaneous BRIUMVI expected to be a significant catalyst for future revenue and earnings growth.
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics announced new clinical data for its multiple sclerosis portfolio at MSToronto2026, showcasing sustained disease control with BRIUMVI over seven years, with approximately 88% of participants free from confirmed disability progression. The company also presented data supporting a simplified single-dose initiation schedule for intravenous BRIUMVI and quarterly subcutaneous dosing, aiming to enhance treatment options for relapsing MS patients. Additionally, initial results from a Phase 1 study evaluating azer-cel in primary progressive MS were highlighted.
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
TG Therapeutics presented new clinical data at MSToronto2026, showcasing sustained disease control with BRIUMVI over seven years, with approximately 88% of participants remaining free from confirmed disability progression. The presentations also included positive Phase 3 ENHANCE results supporting a single-dose initiation schedule for BRIUMVI and Phase 1 subcutaneous data supporting a quarterly dosing schedule. Additionally, an abstract for a late-breaking oral presentation on azer-cel for primary progressive multiple sclerosis was made available, reinforcing confidence in BRIUMVI as a leading treatment option for relapsing MS and highlighting advancements for future formulations.
TG Therapeutics reports seven-year BRIUMVI disability and safety findings
TG Therapeutics (NASDAQ: TGTX) announced updated seven-year findings for its multiple sclerosis drug, BRIUMVI, showing confirmed disability progression in 11.7% of continuously treated patients versus 17.4% in those who switched from an initial comparator. The company also presented data on simplifying infusions and developing an injected formulation, aiming to expand commercial options. These updates come as TG Therapeutics faces established competitors in the MS treatment market, with strong cash reserves to fund its operating plan and upcoming readouts for other programs.
TG Therapeutics, Inc. (TGTX) Stock Forecasts
The article "TG Therapeutics, Inc. (TGTX) Stock Forecasts" is largely a placeholder or an error page from Yahoo Finance. It contains navigation links, advertisements, and general market data but lacks any specific content regarding TG Therapeutics, Inc. (TGTX) stock forecasts or analysis. The page indicates an error in retrieving data, suggesting that the intended content was not loaded.
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
TG Therapeutics (TGTX) stock has surged by 60% in the last six months, primarily driven by the strong sales performance of its drug Briumvi, which treats relapsing forms of multiple sclerosis. The company has raised its 2026 revenue guidance based on Briumvi's strong demand and is also developing the drug for other autoimmune diseases and a self-administered subcutaneous formulation. TG Therapeutics currently holds a Zacks Rank #1 (Strong Buy).
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
TG Therapeutics (TGTX) stock has seen a significant 60% increase over the past six months, primarily driven by strong sales of its multiple sclerosis drug, Briumvi. The company has raised its 2026 total revenue guidance to $950 million, reflecting Briumvi's robust demand. TGTX is also actively developing Briumvi for additional indications, including treatment-resistant schizophrenia and myasthenia gravis, and a self-administered subcutaneous formulation for RMS.
TGTX Stock Rises 60% in 6 Months: Here's What You Should Know
TG Therapeutics' (TGTX) stock has surged by 59.9% in the last six months, driven by strong sales of its multiple sclerosis drug, Briumvi. The company has raised its 2026 revenue guidance based on Briumvi's robust demand and is also conducting studies for Briumvi in other autoimmune diseases and developing a self-administered subcutaneous formulation. Several other biotech stocks, including Werewolf Therapeutics, Arvinas, and Eton Pharmaceuticals, also show strong Zacks Ranks.
TG Therapeutics Inc (NKB2.DU) Stock Price, News, Quote & History
This Yahoo Finance page provides a detailed overview of TG Therapeutics Inc (NKB2.DU) stock, including its current price, historical data, and performance metrics. It shows the stock's significant returns over various periods compared to the S&P 500, along with key financial statistics and company information.
TG Therapeutics (TGTX) Reports Five-Year Study Showing BRIUMVI's Superior Disability Progression Outcomes in RMS
TG Therapeutics (NASDAQ: TGTX) announced results from a five-year comparative study demonstrating BRIUMVI's superior efficacy in reducing disability progression and relapse rates in patients with relapsing multiple sclerosis (RMS) compared to ocrelizumab and ofatumumab. The company, which specializes in B-cell disease treatments, holds a market capitalization of $8.48 billion, and its stock trades at a P/E ratio significantly below its historical median. While the GF Score indicates strong growth and momentum, profitability and valuation remain moderate, and insider selling has been noted despite strong guru accumulation.
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG Therapeutics announced the publication of a five-year matching-adjusted indirect comparison (MAIC) study showing that its drug, BRIUMVI, was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates over five years compared to ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). The company emphasizes the value of this analysis in helping physicians and patients choose among anti-CD20 treatment options for MS, especially in the absence of direct head-to-head trials. The findings suggest durable efficacy for BRIUMVI, though further direct comparative studies are needed for confirmation.
TG Therapeutics publishes five-year Briumvi comparison study
TG Therapeutics announced the publication of a five-year matching-adjusted indirect comparison (MAIC) study analyzing outcomes of its multiple sclerosis drug Briumvi against ocrelizumab and ofatumumab. The study found Briumvi was associated with a lower relative hazard of 24-week confirmed disability progression and longer time free from progression compared to both other drugs. The findings, though exploratory, were funded by Neuraxpharm, TG Therapeutics' European partner.
High Growth Tech Stocks To Watch In US October 2026
This article highlights top high-growth tech stocks in the US for October 2026, noting the market's steady performance and anticipated 18% annual earnings growth. It features companies like TG Therapeutics, Praxis Precision Medicines, and Ciena, detailing their financial performance, growth forecasts, and recent innovations. The piece emphasizes the importance of identifying innovative and adaptable companies in the current market environment.
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG Therapeutics announced the publication of a five-year comparative analysis showing that its drug, BRIUMVI (ublituximab-xiiy), was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates compared to ocrelizumab and ofatumumab in patients with relapsing multiple sclerosis (RMS). The study, a matching-adjusted indirect comparison (MAIC), suggests durable efficacy for BRIUMVI, providing valuable data where head-to-head clinical trials are absent. These findings contribute to the growing evidence supporting BRIUMVI's potential long-term benefits for MS patients.
Articles from TG Therapeutics, Inc.
TG Therapeutics, Inc. announced its schedule of data presentations for the upcoming 10th Joint ACTRIMS-ECTRIMS Meeting, MSToronto2026, from October 21-23, 2026. The presentations will include a late-breaking oral presentation on initial Phase 1 results for azer-cel in primary progressive multiple sclerosis (PPMS) and several presentations on BRIUMVI® (ublituximab-xiiy) in multiple sclerosis (MS).
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics (NASDAQ: TGTX) announced its schedule of data presentations at MSToronto2026, including initial clinical results for azer-cel, an allogeneic CD19-directed CAR T-cell therapy, in progressive multiple sclerosis. The company will also present extensive data on BRIUMVI, covering seven-year clinical outcomes, real-world evidence, pivotal data for its single-dose initiation schedule, and full Phase 1 subcutaneous BRIUMVI results. These presentations aim to highlight the efficacy, safety, and evolving treatment experience of BRIUMVI for patients with multiple sclerosis.
TG Therapeutics (NASDAQ:TGTX) Emerges as an Affordable Growth Play in Biotech
TG Therapeutics (NASDAQ:TGTX) is presented as an "affordable growth" opportunity in the biotech sector. The article highlights the company's rapid revenue expansion and transition to a commercial-stage entity, supported by strong growth metrics and a debt-free balance sheet. While its trailing valuation appears high, the forward price-to-earnings ratio and peer comparisons suggest a more reasonable valuation for its growth prospects.
TG Therapeutics, Inc. (TGTX) Stock forecasts
Argus has lowered its target price for TG Therapeutics, Inc. (TGTX) to $58.00, according to a report published on September 16, 2026. The biopharmaceutical company, which focuses on treatments for B-cell diseases, is currently trading at $55.78. The report provides an earnings estimate and a summary of the company's profile.
TG Therapeutics, Inc. Revenue Breakdown – HAN:NKB2
TG Therapeutics, Inc. generated €524.72 million last year, primarily from its Novel Treatments for B-cell Diseases segment. This revenue marks an increase from the previous year's €317.81 million, with the United States being the sole geographical contributor to these figures.
After tax other income/expense of TG Therapeutics, Inc. – HAN:NKB2
This page from TradingView provides financial information for TG Therapeutics, Inc. (NKB2) listed on the Hannover Stock Exchange. Specifically, it focuses on the "After tax other income/expense" metric for the company. The page also offers navigation to other financial data, news, and community features related to NKB2.
Investigation launched into TG Therapeutics' of...
Kuehn Law, PLLC has launched an investigation into TG Therapeutics, Inc. officers and directors for potential self-dealing and breach of fiduciary duties that may harm shareholders. The legal probe could result in damages for shareholders and corporate governance reforms, and long-term shareholders are encouraged to contact the law firm. As of September 28, 2026, TG Therapeutics (TGTX) was trading at USD 57.30 with a market capitalization of $8.79 billion.
TG Therapeutics, Inc. (TGTX) Options Chain - Yahoo Finance
This Yahoo Finance page displays the options chain for TG Therapeutics, Inc. (TGTX). As of the article's data, there are no calls or puts currently listed for the specified contract date, indicating no available options. The page also provides the stock's current price and after-hours trading information.